Ovensa, a company enabling the development of targeted therapies and delivery systems using proprietary nanoparticle compositions, and Celanese Corporation, a global chemical and specialty materials company, announced plans to collaborate on the long-acting controlled release of targeted therapeutics that address current performance, toxicity and resistance challenges in the market.

The companies will evaluate the synergy of Celanese’s VitalDose EVA copolymer delivery technology for drug-eluting implants and Ovensa’s TRIOZAN Platform for enhanced RNA, mAb and peptide-based molecule drug delivery. Ovensa and Celanese will focus on formulation development, leveraging each organization’s unique technology and expertise.

The companies are optimistic the collaboration will pave the way for breakthrough therapeutic treatments.

“Ovensa’s proprietary TRIOZAN and targeting ligand platforms opens an exciting pathway into the world of targeted and precision medicines,” said Ovensa’s President and CEO,  Stéphane Gagné.

“Our platforms focus on complex diseases and other therapeutic areas such as cancer resistance and diseases of the central nervous system. It’s through strategic collaborations with industry leaders like Celanese that we will develop innovative, long-lasting and life-changing therapies to treat some of the world’s most complex diseases.”

“Celanese is collaborating with Ovensa to evaluate the use of our VitalDose® EVA copolymer delivery technology in conjunction with their TRIOZAN™ nanomedicine and targeting ligand platforms to deliver therapeutics to targeted sites in the body allowing for reduced toxicity and superior performance,” said Jeff Haley, Celanese’s Medical/Pharma Technology & Innovation Leader. “We are excited to explore this opportunity to advance targeted drug delivery to improve therapeutic outcomes for patients all over the world.”